Peptide Therapy: What the Science Actually Says
Peptides like BPC-157 attract significant attention, but the evidence is nuanced. Here's an honest look at what peptide therapy is, what the research shows, and what remains unproven.
Key Takeaways
- Peptides are short chains of amino acids that act as signaling molecules in the body.
- BPC-157 has preclinical (animal) evidence that has attracted attention, but human clinical data remains limited.
- BPC-157 is not FDA-approved for any indication.
- Quality varies significantly between sources, which is why questions about pharmacy licensing, sourcing, and batch testing matter.
- The responsible approach is engaging with the evidence honestly, not overclaiming what the science supports.
Peptide therapy attracts a great deal of consumer interest, and it is also frequently overclaimed. Here's an honest breakdown of what peptides are, what the evidence supports, and where the science still has gaps.
What Are Peptides?
Peptides are short chains of amino acids, the building blocks of proteins. Your body produces thousands of peptides naturally. They act as signaling molecules, telling cells what to do: repair tissue, reduce inflammation, regulate hormones, and more.
Therapeutic peptides are synthetic versions of these natural compounds, designed to amplify specific biological processes.
BPC-157: The Most-Discussed Peptide
BPC-157 (Body Protection Compound-157) is a 15-amino-acid peptide derived from a protein found in human gastric juice. It's the peptide you'll see discussed most frequently in health optimization circles. On Varus, BPC-157 and other peptides are available by consultation only.
What the preclinical evidence shows:
In animal studies, BPC-157 has shown tissue-protective signals that have drawn attention from researchers and consumers. Research in rodent models has reported healing effects in tendons, ligaments, muscles, and the gut lining. Proposed mechanisms include promoting angiogenesis (new blood vessel formation), modulating nitric oxide signaling, and supporting healthy inflammatory responses.
What we need to be honest about:
The majority of BPC-157 research comes from animal models. Human clinical trial data remains limited. This is an important distinction. Promising animal data does not always translate to the same effects in humans.
Because the human evidence base remains limited and the regulatory context is nuanced, Varus presents BPC-157 with explicit evidence and compounding disclosures rather than hype. Transparency about the evidence level matters more than broad claims.
How Peptide Therapy Is Administered
Most therapeutic peptides are administered via subcutaneous injection, similar to insulin. The injections use small needles and are typically performed daily. Some peptides are also available in oral or nasal spray formulations for specific applications.
Peptides are inherently fragile molecules. They must be properly stored (often refrigerated) and handled according to instructions to maintain potency.
Quality Matters
When a peptide is compounded for patient care, quality can vary significantly between sources. Key factors to evaluate:
- Is the peptide sourced from a licensed pharmacy operating within the applicable regulatory framework?
- Are certificates of analysis (COAs) available showing purity and potency?
- Is the peptide pharmaceutical-grade or research-grade? (Only pharmaceutical-grade is appropriate for human use.)
If you are evaluating a peptide program, ask whether the compound is currently offered in the catalog, who prepares it, and what batch-level quality controls are in place.
The Bottom Line
Peptide therapy is an area of ongoing research. Some compounds have intriguing preclinical signals, but the human evidence base is uneven and the field attracts substantial hype.
The responsible approach is to engage with the evidence honestly, work with licensed providers who understand the nuances, and make informed decisions based on your specific health goals.
Frequently Asked Questions
Why does BPC-157 get so much attention?
BPC-157 (Body Protection Compound-157) is a 15-amino-acid peptide that has been studied in animal models exploring tissue repair and gastrointestinal healing. Those preclinical signals are why people talk about it, but they do not establish proven clinical benefit in humans.
Is BPC-157 FDA-approved?
No. BPC-157 is not FDA-approved for any indication. Varus presents it with explicit evidence and compounding disclosures rather than as an FDA-approved or clinically established therapy.
How is peptide therapy administered?
Most therapeutic peptides are administered via subcutaneous injection using small needles, typically once daily. Some peptides are also available in oral or nasal spray formulations. Peptides must be properly stored (often refrigerated) and handled according to instructions to maintain potency.
Related Treatments
Medical services are provided by independent licensed clinicians using the Varus platform. Varus does not provide medical advice, diagnosis, or treatment. Compounded medications are prepared by licensed pharmacies and are not FDA-approved. This content is for educational purposes only and does not constitute medical advice.